Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tardive dyskinesia: An update.

S. K. Kulkarni1, P. S. Naidu

  • 1Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. skpu@yahoo.com

Drugs of Today (Barcelona, Spain : 1998)
|June 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacodynamics of drug-induced weight gain.

Drugs of today (Barcelona, Spain : 1998)ยท2003
See all related articles

Tardive dyskinesia (TD) is a severe motor side effect of long-term neuroleptic treatment. Understanding its pathological mechanisms and developing effective treatments for this persistent condition remain critical research priorities.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Tardive dyskinesia (TD) is a significant motor adverse effect associated with chronic neuroleptic medication.
  • It manifests as involuntary movements, primarily affecting the orofacial region, but can also involve limbs and trunk.
  • A concerning feature of TD is its potential for persistence and irreversibility even after drug cessation.

Purpose of the Study:

  • To review the current understanding of Tardive dyskinesia (TD) pathophysiology.
  • To discuss the limitations of existing therapeutic approaches for TD.
  • To highlight the need for further research into TD mechanisms and treatments.

Main Methods:

  • Review of existing literature on Tardive dyskinesia (TD) etiology and pathophysiology.

Related Experiment Videos

  • Analysis of neurotransmitter system involvement (dopaminergic, GABAergic, serotonergic, noradrenergic).
  • Consideration of emerging research areas like glutamatergic excitotoxicity and oxidative stress.
  • Evaluation of animal models used in TD research (homologous, analogous, correlational).

    • Main Results:

    • While neuroleptic treatment is a known cause, the primary pathological mechanisms of TD are not fully understood.
    • Abnormalities in multiple neurotransmitter systems are implicated.
    • Current therapeutic strategies targeting these systems have limited success in most patients.
    • Animal models provide valuable insights but do not fully replicate the human condition.

    Conclusions:

    • Significant gaps remain in understanding the fundamental pathophysiology of Tardive dyskinesia (TD).
    • Existing treatments are largely ineffective for the majority of patients.
    • Extensive further research is imperative to elucidate TD mechanisms and develop novel, effective therapies.